Phase 3Recruiting
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy (LIONHEART-HCM)
A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Active-Comparator-Controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Sponsor
- Braveheart Bio, Inc. (Industry)
- Enrolment
- 210 planned
- Conditions
- Cardiomyopathy, Hypertrophic Obstructive
- Interventions
- BHB-1893; Metoprolol
- Ages
- adults, older adults
- Registry
- NCT07755904
Full record on ClinicalTrials.gov
From the registry
The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.
Primary outcomes
- Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered